Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
ApexOnco Front Page
Recent articles
The first data are dribbled out, but cross-trial comparisons look uninspiring.
The company scraps its lead project and clears out its C-suite, but there was already a precedent.
An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.
Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.
The company dribbles out more data on IMA203, and the numbers head in the right direction.
ASCO is fast approaching, but in the meantime Olema will have an important readout.
The sale of remaining rights to Allogene ends acrimony between the two companies.